2021
DOI: 10.1200/jco.21.01757
|View full text |Cite
|
Sign up to set email alerts
|

Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 9 publications
0
2
0
Order By: Relevance
“…We appreciate the interest expressed by Shimoi et al 1 and Shimanuki et al 2 in our recent manuscript. 3 They raise thoughtful issues around two main questions.…”
mentioning
confidence: 83%
“…We appreciate the interest expressed by Shimoi et al 1 and Shimanuki et al 2 in our recent manuscript. 3 They raise thoughtful issues around two main questions.…”
mentioning
confidence: 83%
“…HER2 + BC can be treated with monoclonal antibodies against HER2, such as trastuzumab. TNBC does not express specific molecules; therefore, standard cytotoxic chemotherapy (doxorubicin, docetaxel, 5-fluorouracil, platinum drugs, and other agents in different combinations) remains the standard of care for patients with TNBC (Nøhr-Nielsen et al, 2020;Su et al, 2020;Pal and Rakshit, 2021;Shimanuki et al, 2021). However, regardless of the treatment strategy, the potential side effects, including lymphedema, weight reduction, pain, and chemotherapyinduced peripheral neuropathy, are significant (Binkley et al, 2012).…”
Section: Introductionmentioning
confidence: 99%